GGrantIndex
Sort

15,842 grants matching pancreatic cancer

Systemic Inhibition of Monocyte Chemoattractant Protein-1 (MCP-1; CCL2)

$266,856
Robert Loberg · University Of Michigan At Ann Arbor · P50 · FY2011 · CA

CA: GASTROINTESTINAL (GI) TISSUE RESOURCE

$266,855
Achyut Bhattacharyya · University Of Arizona · P50 · FY2011 · CA

Mechanistic and Translational Studies of PR-104:A New Hypoxia Activated Cytotoxin

$266,819
John Martin Brown · Stanford University · P01 · FY2007 · CA

Core B: Biospecimen Core

$266,752
Ryan C Fields · Washington University · P50 · FY2025 · CA

Regulation of Tumor and Metastatic Growth by Hypoxia and CTGF

$266,723
Amato J. Giaccia · Stanford University · P01 · FY2007 · CA

Biospecimen Acquisition, Processing, and Classification Unit

$266,600
Ryan C Fields · Washington University · U2C · FY2020 · CA

Core B – Human Biospecimen and Advanced Sequencing Core

$266,598
Leonidas G Koniaris · Medical University Of South Carolina · P01 · FY2021 · CA

PDX-1 is a Therapeutic Target for Pancreatic Cancer

$266,570
Francis Charles Brunicardi · Baylor College Of Medicine · R01 · FY2011 · CA

Activating liver carcinogens in yeast by expressing CYP450 polymorphisms

$266,250
Michael Thomas Fasullo · Ordway Research Institute, Inc. · R21 · FY2007 · ES

Integrated Small Animal Imaging Research Resource

$266,243
Chin-Tu Chen · University Of Chicago · P30 · FY2018 · CA

Detection and Diagnosis of Pancreatic Cancer

$266,228
Ctr For Molecular Medicine/Immunology · R01 · FY2005 · CA

Immunotherapy of mesothelin expressing tumors with lentiviral engineered T cells

$266,186
Carl H. June · University Of Pennsylvania · R01 · FY2008 · CA

Immunotherapy of mesothelin expressing tumors with lentiviral engineered T cells

$266,186
Carl H. June · University Of Pennsylvania · R01 · FY2009 · CA

Immunotherapy of mesothelin expressing tumors with lentiviral engineered T cells

$266,186
Carl H. June · University Of Pennsylvania · R01 · FY2010 · CA

Pharmacologic /Genetic Inhibition of XBP1 as Hypoxia Targeted Therapeutic Strateg

$266,097
Albert Koong · Stanford University · P01 · FY2010 · CA

Peripheral blood biopsy for molecular diagnosis of pancreatic cancer

$266,061
Sunil R Hingorani · Fred Hutchinson Cancer Research Center · R21 · FY2012 · CA

The Fulvene Approach to the Syntheses of Antitumor Agents

$265,939
Ihsan Erden · San Francisco State University · SC1 · FY2012 · GM

The Fulvene Approach to the Syntheses of Antitumor Agents

$265,939
Ihsan Erden · San Francisco State University · SC1 · FY2011 · GM

Pancreatic Cancer Prevention with NO-releasing NSAIDs

$265,900
State University New York Stony Brook · R01 · FY2004 · CA

Pancreatic Fluid Proteomics in Alcohol Induced Chronic Pancreatitis

$265,878
Darwin Lewis Conwell · Brigham And Women'S Hospital · R21 · FY2010 · DK

Development of molecular probes for biomedical applications

$265,770
Weihong Tan · University Of Florida · R01 · FY2007 · GM

Animal Core

$265,748
Guido Erwin Michael Eibl · University Of California Los Angeles · P01 · FY2014 · CA

Cytoskeletal Dynamics in Pancreatic Cancer Metastasis

$265,742
Mark A. Mc Niven · Mayo Clinic Rochester · R01 · FY2006 · CA

Enhanced Chemosensitivity of Pancreatic Cancer

$265,742
M Guillaume Wientjes · Ohio State University · R01 · FY2006 · CA

Biospecimen Acquisition, Processing, and Classification Unit

$265,733
Ryan C Fields · Washington University · U2C · FY2022 · CA